Aquestive Therapeutics, Inc. (AQST) - Stock Analysis?

Aquestive Therapeutics, Inc. (AQST) - Stock Analysis?

WebSep 23, 2024 · AQST stock forecast; Aquestive Therapeutics stock forecast 2024 - 2025 - 2030 with analysis ... Aquestive Therapeutics stock forecast for 2024 is $1.05, forecast for 2024 is $1.15, forecast for 2024 is $1.81, forecast for 2025 is $2.0, forecast for 2026 is $2.03, forecast for 2027 is $1.96, forecast for 2028 is $1.71, forecast for 2029 is $1.19 ... WebThe 6 analysts offering 1 year price forecasts for AQST have a max estimate of — and a min estimate of —. Analyst rating Based on 6 analysts giving stock ratings to AQST in … best gluten free flour for gumbo roux WebMar 24, 2024 · The current AQST price target is $6.13. Learn why top analysts are making this price prediction for Aquestive Therapeutics at MarketBeat. Skip to main content. S&P 500 . DOW . QQQ 310.89. ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the … WebAquestive Therapeutics (AQST) will release its next earnings report on May 10, 2024. In the last quarter Aquestive Therapeutics reported -$0.226 EPS in relation to -$0.23 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports ... best gluten free flourless chocolate cake recipe WebSee the AQST stock price predictions generated by our AI models, including high, low and average values. These predictions can range from one-week to monthly, or even 12-month, time spans. WebMar 24, 2024 · Based on short-term price targets offered by four analysts, the average price target for Aquestive Therapeutics comes to $6.38. The forecasts range from a low of $4.00 to a high of $9.50. The ... best gluten free food in indianapolis WebAccording to . 4 Wall Street analysts that have issued a 1 year AQST price target, the average AQST price target is $6.13, with the highest AQST stock price forecast at …

Post Opinion